ArticleMolecular biomedicine2026
Targeting the Calcineurin Homologous Protein 1 (CHP1)-Transmembrane Protein 87A (TMEM87A) mechanosensing complex: a druggable vulnerability in metastatic ovarian cancer.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite advances in treatment, metastatic high-grade serous ovarian carcinoma (HGSC) remains largely incurable, and the molecular machinery enabling tumor cells to survive detachment and disseminate intraperitoneally remains poorly understood. HGSC metastasis requires tumor cells to evade anoikis during detachment from the fallopian tube epithelium. Through integrative analysis of hyaluronic acid (HA) metabolism-associated genes in transcriptomic datasets, calcineurin homologous protein 1 (CHP1) was identified as a novel mediator of HGSC metastasis. Mechanistically, CHP1 ablation disrupted spheroid morphogenesis in 3D models, inducing aberrant multi-spheroid formation and reduced structural integrity, with impaired cell extrusion from mosaic spheroids. Bioinformatic and experimental validation revealed that CHP1 interacted with the mechanosensitive channel transmembrane protein 87A (TMEM87A), forming a putative mechanosensing complex that may regulate metastasis via the YAP-GPC6-WNT5A/Hedgehog signaling axis; knockout of either gene downregulated WNT5A/GPC6 and inhibited WNT5A/Hedgehog pathways. In vivo, CHP1 or TMEM87A knockout significantly suppressed orthotopic tumor growth and metastasis in NSG mice, indicating a role in overall tumor progression beyond metastasis alone. Drug repurposing identified sodium gluconate (a TMEM87A modulator) as a therapeutic candidate: low-dose treatment (1 mg/kg, weekly) significantly reduced tumor burden by disrupting CHP1-TMEM87A binding and inhibiting downstream Hedgehog/PTCH1 signaling, as the cellular thermal shift assay (CETSA), microscale thermophoresis (MST), surface plasmon resonance (SPR), and co-immunoprecipitation. Clinically, high CHP1/TMEM87A expression exhibited stage-dependent prognostic significance (favorable in early-stage, unfavorable in late-stage HGSC), as assessed by Kaplan-Meier survival analysis of publicly available datasets. These findings suggest that the CHP1-TMEM87A complex may serve as a mechanosensitive regulator of HGSC metastasis and propose gluconate-based targeting as a promising therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.